Loading organizations...
§ Venture Capital · Switzerland
Swiss biopharmaceutical company developing novel therapies, in-licensing and out-licensing drugs for oncology and infectious diseases.
Debiopharm is a Lausanne, Switzerland-based biopharmaceutical company that identifies, in-licenses, develops, and out-licenses novel therapeutic treatments specifically targeting oncology and infectious diseases. The privately held firm acquires promising early-stage compounds from academic universities and biotechnology startups, advances them through rigorous clinical development and GMP manufacturing at its Martigny facilities, and subsequently partners with larger pharmaceutical corporations for worldwide commercialization. Operating with a total workforce of approximately 450 employees, the organization currently maintains an active clinical pipeline consisting of 15 ongoing drug research programs. Under the strategic direction of President Thierry Mauvernay and CEO Bertrand Ducrey, the enterprise has successfully developed widely used blockbuster drugs such as oxaliplatin and triptorelin, while also expanding its operational footprint into infectious disease diagnostics through the strategic acquisition of GenePOC. Debiopharm was officially founded in 1979 by Swiss entrepreneur Rolland-Yves Mauvernay.
Key people at Debiopharm.
Debiopharm is a privately-held Swiss biopharmaceutical company specializing in the development and clinical testing of innovative drug candidates, primarily in oncology and infectious diseases. It focuses on in-licensing promising compounds, advancing them through clinical development, and partnering with global pharmaceutical companies for commercialization. Debiopharm aims to develop tomorrow’s standard of care to cure cancer and infectious diseases and improve patient quality of life, with a pipeline that includes oncology, antibiotic, rare disease, and antibody-drug conjugate (ADC) technologies[1][3][4][5].
Founded in 1979 by Dr. Rolland-Yves Mauvernay in Martigny, Switzerland, Debiopharm was born from the conviction that many potentially useful therapeutic products were abandoned before reaching their full potential. Early on, the company focused on developing triptorelin, a gonadotropin-releasing hormone (GnRH) agonist, and later oxaliplatin, a platinum-based chemotherapy drug. Both drugs became standards of care and generated significant revenue, establishing Debiopharm’s reputation. The company has since evolved to focus on in-licensing innovative compounds and advancing them through clinical development to address high unmet medical needs[1][4].
Debiopharm rides the global trend of precision medicine and targeted therapies, particularly in oncology and infectious diseases, where there is a critical need for new treatments due to resistance and unmet patient needs. The timing is favorable given advances in drug conjugation technologies and increasing antibiotic resistance. By bridging early-stage discovery and global commercialization, Debiopharm plays a pivotal role in accelerating access to innovative therapies and shaping the biopharmaceutical ecosystem in Switzerland and beyond[3][4][5].
Looking ahead, Debiopharm is poised to expand its impact by advancing its pipeline of novel oncology and antibiotic candidates, including sustained-release formulations and pathogen-specific antibiotics that spare the microbiome. Trends such as personalized medicine, antibiotic resistance, and antibody-drug conjugates will likely shape its development strategy. Its unique in-licensing and partnership model provides agility to adapt to scientific advances and market needs, positioning Debiopharm to continue influencing global standards of care in cancer and infectious diseases[4][5]. The company’s commitment to innovation and patient outcomes suggests a sustained role as a key biopharmaceutical innovator.
Debiopharm has 7 tracked investments across 7 companies. The latest tracked deal is $3.0M Seed in Tune Insight in September 2023.
Key people at Debiopharm.
